Skip to NavigationSkip to content


Boehringer and Vitae Pharma drug fails in mid-stage trial

BI building
Image: Boehringer Ingelheim GmbH

A pipeline diabetes drug co-developed by Vitae Pharma and German giants Boehringer Ingelheim has failed to show benefits in a Phase II trial.

Pennsylvania-based Vitae Pharma said the proof-of-concept study, which looked at the investigational diabetes treatment BI187004/VTP-34072 in combination with metformin, failed to reach its primary endpoint – reducing fasting blood sugar levels.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches